Evaluation of cilazapril in vasovagal syncope treatment

Objective: to evaluate cilazapril in vasovagal syncope treatment. Method: eighty-six cases of VVS patients found positive in TTT tilt were medicated with 2.5 mg cilazapril daily for three months and followed up by TTT. Results: seven cases quit due to cough or unexplained reason; 79 VVS patients had no more fainting spells; 75.95% of TTT results of patients changed to negative after 3 months therapy. The before and after cilazapril treatment average blood pressures (taken in lying position) were 121/73 mm Hg (1 mm Hg=0.133kPa) and 120/76 mm Hg respectively (P>0.05); and mean heart rates were 68.63±12.37/min and 70.13±13.15/min respectively with no significant changes (P>0.05). Conclusion: Cilazapril was effective in treatment of VVS; did not affect normal blood pressure and heart rate; was safe; and had little side effect.